Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06139575 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 6 months later May 2026 → Dec 2026
See other at-risk trials from Bivision Pharmaceuticals, Inc.

Record History

  1. Primary completion pushed from May 2026 to Dec 2026 Eligibility criteria expanded, about 14 words · Secondary endpoints: details revised at 2 of 16 entries · Site details revised at 1 of 13 sites Show 3 more changesShow less
    • Eligibility criteria expanded, about 14 words
    • Secondary endpoints: details revised at 2 of 16 entries
    • Site details revised at 1 of 13 sites
  2. Primary endpoints revised (4) Study sites: 1 to 13 · Secondary endpoints revised (16)v4 Show 2 more changesShow less
    • Study sites: 1 to 13
    • Secondary endpoints revised (16)

    See this version in full on ClinicalTrials.gov ↗

  3. Study Identification, Study Status, Oversightv3
  4. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Dec 2023 to Dec 22, 2023v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 2023 to Dec 22, 2023
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary efficacy of Lutetium Lu 177 JH020002 Injection in adult patients with advanced prostate cancer.
Trial Details
NCT Number NCT06139575
Lead Sponsor Bivision Pharmaceuticals, Inc.
Conditions Prostate Cancer
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov